Stem Cell Sciences plc today announced that the UK Patent Office has granted it a patent covering the Company’s new range of stem cell culture media. The new Culticell iSTEM range uses the inhibitor based technology discovered by Professor Austin Smith and recently published in Nature (vol. 453, pp.519-523).

continue reading.....

Samaritan Pharmaceuticals has announced that it has filed an IND (Investigational New Drug) application for SP-6310 in the treatment of HIV-infected patients with abnormal cortisol levels.

continue reading.....

Eli Lilly and Company and SGX Pharmaceuticals, Inc. today announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction. SGX, based in San Diego, California, is a biotechnology company focused on drug discovery and development in the area of oncology.

continue reading.....

A meta-analysis of 19 major studies of preoperative statin therapy, given for an unrestricted period of time prior to cardiac surgery of all types, resulted in a 1.5% absolute risk reduction and a 43% odds reduction for early all-cause mortality, compared with patients undergoing cardiac surgery who were not on statins prior to the operation.
Reuters Health Information

continue reading.....

A meta-analysis of 19 major studies of preoperative statin therapy, given for an unrestricted period of time prior to cardiac surgery of all types, resulted in a 1.5% absolute risk reduction and a 43% odds reduction for early all-cause mortality, compared with patients undergoing cardiac surgery who were not on statins prior to the operation.
Reuters Health Information

continue reading.....

Two years after the end of potentially neurotoxic intrathecal and systemic chemotherapy, no major differences in neuropsychological outcome were found between pediatric patients with acute lymphoblastic leukemia (ALL) and their healthy siblings.
Reuters Health Information

continue reading.....

Two years after the end of potentially neurotoxic intrathecal and systemic chemotherapy, no major differences in neuropsychological outcome were found between pediatric patients with acute lymphoblastic leukemia (ALL) and their healthy siblings.
Reuters Health Information

continue reading.....

The addition of metformin to a lifestyle modification program may help female adolescents lose weight if they also make dietary changes, according to findings published in the June issue of the Journal of Pediatrics.
Reuters Health Information

continue reading.....

The addition of metformin to a lifestyle modification program may help female adolescents lose weight if they also make dietary changes, according to findings published in the June issue of the Journal of Pediatrics.
Reuters Health Information

continue reading.....

We will be launching the new platform for NeLM tomorrow (Thursday 10th July). This means that you will need to re-subscribe to ensure that you continue to receive your daily email updates. The new version of the website will enable us to provide you with an update service that more closely meets your specific information requirements about medicines. From Wednesday the daily email update will consist of news, notification about new evidence concerning medicines (classified as drug specific reviews, disease-orientated reviews, drug- class focussed reviews, reviews about adverse effects and reviews that focus on complementary medicine) as well as other updates.

<b>If you are an NHS user</b>, please complete the registration form accessed from the "Register" hyperlink text at the top right hand side of the screen. This will enable you to access all areas of the website including additional information about horizon scanning, drug shortages and access to NPA resources under “Community Areas”. You will receive a registration confirmation email. Only after you follow the link from the email will you be able to access NHS restricted material.

You will then need to click on "Update Newsletter Subscription" and select "Horizon Scanning" if you wish this NHS restricted material to be included in your Newsletter

<b>If you are a non-NHS user</b> simply click on the box titled "NeLM newsletter" - in this case all we require is an email address and you will get a daily email update notifying you about new material, and allowing you access to that material, on all areas of the website except those listed above which are restricted to NHS users.

In both cases by selecting from the options offered you can ensure that you are kept informed when particular areas on the site are updated or when products which are relevant to the medical specialities that you have selected are updated. Should you choose the personalisation option you will receive notification of all the news added to the site that day but only details of other additions to the site that are relevant to your chosen area(s) of interest. This is under review and we would value your feedback on whether this best meets your requirements.

Please note that users who request that the Newsletter is sent to their nhs.net emails, the Newsletter will look a little different. We are hoping to improve the formatting of the Newsletter being sent to nhs.net emails.

Please be aware that the RSS feed URLs will be changing so you will also need to update your RSS readers.

Administrators of websites that link to NeLM records, please accept our apologies as our deep-link urls will be changing. Unfortunately as the final data migration is occurring immediately prior to launch you will not be able to change your links till the new NeLM site is launched.

If you were a trial volunteer and subscribed to the Newsletter on the new site prior to the launch date you will need to update your subscription preferences as the NeLM site areas have changed slightly.

Finally we hope that you find the new site more intuitive and user friendly and we would welcome your feedback (click on Site Feedback at the top of the site, or contact us at nelm_support@gstt.nhs.uk) on any aspect of this version. It is however important to note that we will be introducing some more features to the site during the next 6-9 months and again we would welcome volunteers to assess these and provide feedback (again please click on Site Feedback or contact us at nelm_support@gstt.nhs.uk).

Thank you for your support for NeLM over the last 3 years and DrugInfoZone for the 4 years before that and we hope that you find that the new site continues to meet your evolving information needs.

continue reading.....